Mainstream

Icon signals $8B full-year revenue midpoint as metabolic and obesity trial momentum builds

Icon signals $8B full-year revenue midpoint as metabolic and obesity trial momentum builds

Post ContenticlrRead More

You might also be interested in reading TJX gains after earnings show consumers are seeking out value; ROST and BURL also higher.

July 24, 2025
In Mainstream